Trial Profile
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Mar 2023
Price :
$35
*
At a glance
- Drugs Tomivosertib (Primary)
- Indications Head and neck cancer; Lung cancer; Non-small cell lung cancer; Renal cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Effector Therapeutics
- 20 Mar 2023 Status changed from active, no longer recruiting to completed.
- 30 Oct 2020 Planned End Date changed from 1 Mar 2020 to 1 Mar 2021.
- 30 Oct 2020 Planned primary completion date changed from 1 Mar 2020 to 1 Jan 2021.